How the FDA Approves a New Drug
Getting a medicine from the lab to your pharmacy takes a decade or more and clears three phases of human trials. Here is what each stage tests, and why it takes so long.
Photo: Wikimedia Commons, via Wikimedia Commons (CC BY-SA)
When a new drug reaches the market, it is the end of a long, expensive, and heavily regulated journey, often more than a decade in the making. The Food and Drug Administration (FDA) oversees that process in the United States, and its job is to make sure a drug is both safe and effective before it can be sold. Here is how a medicine gets from a lab bench to a pharmacy shelf.
Step one: preclinical research
Before a drug is ever given to a person, it goes through preclinical testing in the lab and in animals. Researchers look for signs that the compound might work and, just as important, screen for obvious toxicity. Only a small fraction of compounds that show promise here ever make it further.
If the results justify human testing, the developer files an Investigational New Drug (IND) application with the FDA, essentially asking permission to begin clinical trials in people.
Step two: the three trial phases
Human testing happens in three phases, each larger than the last:
- Phase 1 focuses on safety and dosage, in a small group of roughly 20 to 100 healthy volunteers or patients. The question is: is it safe, and at what dose?
- Phase 2 tests effectiveness and side effects in up to several hundred people who have the target condition. The question is: does it appear to work, and what are the risks?
- Phase 3 is a large-scale confirmation, often several hundred to a few thousand patients, comparing the drug against a placebo or existing treatment. The question is: does the benefit hold up in a big, diverse group?
Each phase is a gate. Many promising drugs fail at Phase 2 or 3 when a hoped-for benefit does not materialize or side effects prove too serious.
Step three: FDA review
If the trials succeed, the developer submits a formal application: a New Drug Application (NDA) for a conventional drug, or a Biologics License Application (BLA) for a biologic such as a vaccine or antibody. FDA scientists review the full body of evidence, the manufacturing process, and the proposed labeling, and decide whether to approve the drug.
Why it takes so long
From initial discovery to approval, the whole process commonly takes 10 to 15 years, with the clinical trials alone often running 6 to 7 years. The length reflects a deliberate trade-off: rushing risks approving something unsafe or ineffective, while caution delays access to treatments that work. Balancing those two harms is the core of the FDA's job.
Every approved drug represents a bet that its benefits outweigh its risks for a defined group of patients. That is why approvals come with specific labeling about who should take it and how.
After approval: it does not stop
Approval is not the finish line. Phase 4, or post-market surveillance, continues to monitor a drug once large numbers of people are using it in the real world. Rare side effects that trials were too small to catch can surface here, and can lead to new warnings or, occasionally, a withdrawal.
Faster lanes for urgent needs
For serious conditions with few treatments, the FDA has expedited pathways, such as accelerated approval and breakthrough therapy designation, that can speed parts of the process, often by allowing earlier evidence while requiring follow-up studies. These pathways trade some up-front certainty for faster access, and they are used selectively.
The takeaway
The drug approval process is slow because it is designed to be thorough: preclinical work, three escalating phases of human trials, a rigorous FDA review, and ongoing monitoring after launch. It is not perfect, and it involves genuine trade-offs between speed and safety, but it is why medicines sold in the US come with a strong evidence base. The FDA publishes the details of each step for anyone who wants to dig deeper.